RIPK2 Induces Docetaxel Resistance in Prostate Cancer through the NF-κB/P-Gp Signaling Pathway

Researchers elucidated the role and mechanism of action of receptor-interacting protein kinase 2 (RIPK2) in prostate cancer cell resistance to docetaxel.